Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 5/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 7/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935402 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1ALDH1A1MMP2MMP9 | |
| SCHEMBL14935536 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1ALDH1A1MMP2MMP9 | |
| SCHEMBL12378835 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1ALDH1A1MMP2FPR2 | |
| SCHEMBL9584263 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2NPSR1ALDH1A1MMP2MMP9 | |
| SCHEMBL12378834 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2NPSR1ALDH1A1MMP2ADAMTS5 | |
| SCHEMBL11767593 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2NPSR1ALDH1A1MMP2HSD17B10 | |
| SCHEMBL11701498 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2NPSR1ALDH1A1MMP2ADAMTS5 | |
| SCHEMBL11700800 | 0.75 | NPSR1 (0.50) | SMN1; SMN2NPSR1ALDH1A1MMP2ADAMTS5 | |
| SCHEMBL8240781 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2NPSR1ALDH1A1MMP2FPR2 | |
| SCHEMBL13792422 | 0.73 | SMN1; SMN2 (0.84) | SMN1; SMN2NPSR1ALDH1A1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3103797-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3103797-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2776403-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR2, FPR3 | SMN1; SMN2 4512/4885NPSR1 63/4885ALDH1A1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.